

In the Claims:

Please amend the claims by deleting the text shown as strikethrough and adding the text shown in underline.

- 1.(currently amended) A method of monitoring or and/or modulating disease-associated activatory processes comprising determining or and/or influencing the amount or and/or activity of caspase-10 or caspase-10 isoforms in a cell or an organism, wherein the activatory processes are triggered by non-apoptosis signals emanating from death receptors or and/or non-apoptosis signals emanating from non-death receptor members of the TNF receptor family.
- 2.(original) The method of claim 1 wherein the activatory processes are triggered by receptor-crosslinking.
3. (currently amended) The method of claim 1 or 2, wherein the activatory processes are triggered by non-apoptosis signals emanating from death receptors selected from ,particularly TRAIL-R1, TRAIL-R2, CD95, TNF-K1 (pSS TNF-R), TRAMD, DR6 and or combinations thereof.
4. (currently amended) The method of claims 1 or 2, wherein the activatory processes are triggered by signals emanating from non-death receptor members of the TNF receptor family and/or from death receptor members of the TNF receptor family or and/or members of the TLR receptor family.
5. (currently amended) The method of any one of claims 1 or 2 to 4, wherein the disease is selected from hyperproliferative, inflammatory and auto-immune diseases.
6. (original) The method of claim 5, wherein the disease is an inflammatory disease selected from skin inflammatory diseases and septic shock.
7. (original) The method of claim 5, wherein the disease is a hyperproliferative disease selected from tumors.
8. (original) The method of claim 5, wherein the disease is an auto-immune disease.

9. (currently amended) The method of any one of claims 1 or 2 ~~to~~ 8 comprising monitoring the presence, amount, localization or ~~and/or~~ activity of caspase-10 or caspase-10 isoforms in a sample.

10. (original) The method of claim 9, wherein caspase-10 or caspase-10 isoforms are determined on the nucleic acid level.

11. (original) The method of claim 9, wherein caspase-10 or caspase-10 isoforms are determined on the protein level.

12. (currently amended) The method of any one of claims 1 or 2 ~~to~~ 8 comprising modulating the amount or ~~and/or~~ activity of caspase-10 or caspase-10 isoforms in a cell or an organism.

13. (currently amended) The method of claim 12, wherein the amount or ~~and/or~~ activity of caspase-10 or caspase-10 isoforms is modulated on the nucleic acid level.

14. (currently amended) The method of claim 12, wherein the amount or ~~and/or~~ activity of caspase-10 or caspase-10 isoforms is modulated on the protein level.

15. (currently amended) A method of identifying or ~~and/or~~ characterizing compounds for the modulation of disease-associated activatory processes comprising determining if a test compound is capable of influencing the activity of caspase-10 or caspase-10 isoforms, wherein the activatory processes are triggered by non-apoptosis signals emanating from death receptors or ~~and/or~~ non-apoptosis signals emanating from non-death receptor members of the TNF receptor family.